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a b s t r a c t
Those with type 1 diabetes (T1D) are more likely to suffer a fracture than age- and sex-matched individuals without diabetes, despite daily insulin therapy. In rodent studies examining the effect of bone- or glucose-targeting
therapies on preventing the T1D-related decrease in bone strength, insulin co-therapy is often not included, despite the known importance of insulin signaling to bone mass accrual. Therefore, working toward a relevant preclinical model of diabetic bone disease, we assessed the effect of continuous subcutaneous insulin infusion (CSII)
therapy at escalating doses on preserving bone and the effect of delayed CSII on rescuing the T1D-related bone
deterioration in an established murine model of T1D. Osmotic minipumps were implanted in male DBA/2 J
mice 2 weeks (prevention study) and 6 weeks (rescue study) after the ﬁrst injection of streptozotocin (STZ) to
deliver insulin at 0, 0.0625, 0.125, or 0.25 IU/day (prevention study; n = 4–5 per dose) and 0 or 0.25 IU/day (rescue study; n = 10 per group). CSII lasted 4 weeks in both studies, which also included age-matched, non-diabetic
DBA/2 J mice (n = 8–12 per study). As the insulin dose increased, blood glucose decreased, body weight increased, a serum maker of bone resorption decreased, and a serum marker of bone formation increased such
that each end-point characteristic was linearly correlated with dose. There were insulin dose-dependent relationships (femur diaphysis) with cross-sectional area of cortical bone and cortical thickness (micro-computed tomography) as well as structural strength (peak force endured by the mid-shaft during three-point bending).
Likewise, trabecular bone volume fraction (BV/TV), thickness, and number (distal femur metaphysis) increased
as the insulin dose increased. Delayed CSII improved glycated hemoglobin (HbA1c), but blood glucose levels
remained relatively high (well above non-diabetic levels). Interestingly, it returned the resorption and formation
markers to similar levels as those seen in non-T1D control mice. This apparent return after 4 weeks of CSII translated to a partial rescue of the structural strength of the femur mid-shaft. Delayed CSII also increased Tb.Th to
levels seen in non-T1D controls but did not fully restore BV/TV. The use of exogenous insulin should be considered in pre-clinical studies investigating the effect of T1D on bone as insulin therapy maintains bone structure
without necessarily lowering glucose below diabetic levels.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Individuals affected with type 1 diabetes (T1D) are 6 times more
likely to suffer a fracture than the non-diabetic population
(Janghorbani et al., 2007), and low areal bone mineral density (aBMD)
is associated with poor glycemic control (Danielson et al., 2009). Even
though T1D patients receive insulin via multiple daily injection therapy
⁎ Corresponding author at: University of Kentucky, UK Barnstable Brown Diabetes
Center, 830 S. Limestone St., Lexington, KY 40536, United States.
E-mail address: fowlkesjohnl@uky.edu (J.L. Fowlkes).

(MDI) or via continuous subcutaneous insulin infusion therapy (CSII) to
achieve glycemic control, they have a greater fracture risk in adulthood
compared to age- and sex-matched non-diabetic individuals (Weber
and Schwartz, 2016). The reason for this elevated risk is not entirely explained by low aBMD (Vestergaard, 2007), the primary clinical measurement to predict fracture risk. Thus, there is a need for pre-clinical
models that mimic the human condition in order to identify the deleterious changes to bone that explain how T1D increases fracture risk or
decreases fracture resistance.
The administration of streptozotocin (STZ), which is cytotoxic to
beta cells of the pancreas, is a well-established rodent model of T1D.

http://dx.doi.org/10.1016/j.bonr.2017.07.001
2352-1872/© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The toxin causes a reduction in insulin production and subsequent hyperglycemia with the severity depending on the strain of the rodent
(Rodrigues et al., 1997; Shimizu et al., 2012) and the dose of STZ
(Ventura-Sobrevilla et al., 2011). Typically induced between 11-week
to 14-week of age in either mice or rats, STZ-T1D impedes normal
bone mass accrual resulting in lower structural strength of cortical
bone and reduced trabecular bone within several weeks as compared
to non-diabetic controls (Nyman et al., 2011; Silva et al., 2009). The
resulting hypoinsulinemia/hyperglycemia in the STZ model also affects
the material properties of cortical bone (fracture resistance independent of bone structure), but durations of T1D exceeding 8 weeks and
14 weeks are required before signiﬁcant differences in material strength
and toughness between diabetic and control rodents, respectively, are
typically observed (Nyman, 2012).
Despite the known importance of insulin signaling in osteoblasts
to bone mass accrual (Fulzele et al., 2010; Thrailkill et al., 2014), insulin co-therapy is not always included in pre-clinical studies investigating the effect of bone- or glucose-targeting therapies on
preventing the T1D-related decrease in bone strength (Altan et al.,
2007; Glorie et al., 2014; Maycas et al., 2016; Thrailkill et al., 2016;
Zhang et al., 2014). In early rat studies, daily subcutaneous injections
of insulin improved the structural strength of the femur mid-shaft
(Dixit and Ekstrom, 1980) and femoral neck (Hou et al., 1993)
when compared to untreated alloxan-induced T1D rats. Recent rat
studies report daily subcutaneous injections of insulin nearly restored the STZ-related loss i) in peak force endured by the femur
mid-shaft during three-point (3 pt) bending (Rao Sirasanagandla et
al., 2014), ii) in total femur aBMD (Zhang et al., 2008), iii) in femoral
neck and mid-shaft diameters (Abd El Aziz et al., 2015), iv) in femur
mid-shaft aBMD (but not in tensile mechanical properties) (Erdal et
al., 2012), and v) in peak bending stress (but not in peak force during
3 pt. bending) of the tibia mid-shaft (Bortolin et al., 2016). While the
insulin dosing (~ 2 IU/day) tended to be similar among these studies,
discrepancies in the protective effect on mechanical properties could
be due to other experimental factors (e.g., age and strain of the rat,
duration of T1D before therapy, dose of STZ, method of mechanical
testing). There are at least two rat studies of T1D involving 4 weeks
of CSII: one reporting an improvement in trabecular bone volume
fraction with treatment compared to untreated rats (Hie et al.,
2011) and one reporting no treatment effect on the osteointegration

of miniscrews even when combined with intermittent parathyroid
hormone (PTH) injections (Rybaczek et al., 2015).
To the best of our knowledge, there are no rodent studies reporting
how variable insulin therapy, delivered as escalating doses of insulin via
CSII, impacts bone early in the course of T1D (i.e., ﬁrst 4 weeks of
established diabetes) or whether delayed insulin therapy could also be
beneﬁcial in promoting bone strength in T1D. Therefore, we ﬁrst studied
the dose-dependent relationship between insulin therapy and bone
strength in mice by assessing the effect of continuous insulin delivery
on cortical structure and trabecular architecture in the early phase of
diabetic bone disease. Next, we studied the effect of starting CSII after
~ 4 weeks of persistent STZ-induced T1D on mouse bone. The two
hypotheses then were: i) CSII early in the course of T1D could
prevent the diabetes-induced deterioration of cortical bone structure
and strength as well as the deterioration of trabecular bone
microarchitecture in a dose-dependent fashion (prevention study)
and ii) CSII could rescue the diabetes-induced deterioration of cortical
bone structure and trabecular bone microarchitecture (Study 2: rescue
study). In both studies, CSII lasted for 4 weeks (see Fig. 1 for speciﬁcs
of each study design).
2. Materials and methods
2.1. Study design
2.1.1. Prevention study
Over 5 days, 11-week old, male, DBA/2 J mice (The Jackson Laboratories, Bar Harbor, ME) received intraperitoneal (ip) injections of STZ at 40
mg/kg/day in 100 mM citrate buffer. After conﬁrming persistent hyperglycemia (non-fasting blood glucose remaining above 250 mg/dl), 13week, STZ-diabetic mice were treated with saline vehicle (0.0 dose) or
insulin (Humulin R Insulin, Eli Lilly and Co., Indianapolis, IN) at 1 of 3
doses (0.0625, 0.125, and 0.25 IU/day; n = 4–5 per group) using an osmotic minipump (Model 2004, ALZET®, Cupertino, CA) for 4 weeks and
then euthanized. Following the instructions from the manufacturer, the
Alzet pump was implanted subcutaneously in the left anterodorsal region. Matched for age, additional male DBA/2 J mice were also administered ip injections of STZ at 40 mg/kg/day (T1D: n = 9 but 8 individual
femurs available for analysis) or only buffer (100 mM citrate buffer)
over 5 days (non-T1D: n = 10) and euthanized at 17-weeks without

Fig. 1. Overview of the two study designs. In the prevention study, insulin was administered via CSII at escalating doses early in T1D duration. Non-diabetic and diabetic mice were agematched to the mice receiving the insulin pumps in order to establish the effect of diabetes on bone. In the rescue study, insulin therapy did not commence until 6 weeks after the ﬁrst STZ
injection (arrows).

J.S. Nyman et al. / Bone Reports 7 (2017) 1–8

treatment (Fig. 1). Two mice died within 3 weeks of the STZ injection
(STZ-T1D with no pump and STZ-T1D-i0.0625), and one mouse died
within 2 weeks of receiving the Alzet pump (STZ-T1D-i0.0).
2.1.2. Rescue study
12-Week old, male, DBA/2 J mice (The Jackson Laboratories, Bar Harbor, ME) received ip injections of STZ (T1D) or citrate buffer (non-T1D, n
= 12) as described for the prevention study. After 4 weeks of conﬁrmed
T1D (non-fasting blood glucose N 250 mg/dl per week), an Alzet
minipump was implanted subcutaneously in the left anterodorsal region of each T1D mouse (18-weeks of age) to continuously deliver either saline (n = 11 instead of 12 because 1 died within 5 weeks) or
0.25 units/day of insulin (n = 10 instead of 12 because 2 died within
5 weeks). Matched for age, non-T1D mouse group also received continuous saline via the same minipump technique (Fig. 1). All mice were euthanized 4 weeks after pump implantation at 22-weeks of age.
For both studies, non-fasting glucose levels were monitored weekly
with a glucometer (OneTouch® Ultra®2 Blood Glucose Monitoring System, Lifescan, Inc., Milpitas, CA). Following euthanasia, the left femurs
were stored in phosphate buffered saline (PBS) at −20 °C. All animal
procedures followed a protocol approved by the University of Kentucky
Institutional Animal Care and Use Committee or the University of Arkansas for Medical Sciences Institutional Animal Care and Use
Committee.
2.2. Biochemical measurements
Procollagen type 1 N-terminal propeptide (P1NP) was measured in
serum, from blood collected at sacriﬁce, using the Rat/Mouse P1NP Enzyme immunoassay (Immunodiagnostics Systems, Inc., Fountain Hills,
AZ; #AC-33F1). C-terminal telopeptides of type I collagen (RatLAPs)
were measured in serum at sacriﬁce using the RatLAPs ELISA (Immunodiagnostics Systems, Inc., Fountain Hills, AZ; #AC-06F1). HbA1c was
measured on whole blood (Crystal Chem, Downers Grove, Ill. #80310).
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2011), 1.48 mm of the metaphysis at a set distance from the growth
plate was evaluated to determine trabecular parameters using a noise
ﬁlter (standard deviation of 0.2 and support of 2) and global threshold
of 417.3 mgHA/cm3 (prevention study) or 381.1 mgHA/cm3 (rescue
study).
2.4. Three-point bend testing
Following the same procedures described in our previous publications (Nyman et al., 2011; Thrailkill et al., 2014), each hydrated femur
mid-shaft was loaded to failure at 3 mm/min in three-point bending
with a span of 8 mm. The stiffness and structural strength were determined from the resulting force vs. displacement curve as the slope of
the initial linear portion of the curve and the peak force endured by
the bone, respectively. Using the moment of inertia (Imin), cross-sectional area of the cortex (Ct.Ar), and the distance between the centroid
and the outer most point in the anterior-posterior direction (cmin) from
the μCT evaluation of the femur mid-shaft, we estimated bending
strength and span-adjusted toughness (Uppuganti et al., 2016).
2.5. Statistical analysis
The Mann-Whitney test was used to determine whether each bone
property or measurement signiﬁcantly differed between STZ-T1D and
Non-T1D or between STZ-i0.25 vs. Non-T1D. To determine whether
dose-dependent relationships existed while minimizing the number of
animals per group, a linear regression between each property or measurement (bootstrapped with 500 replicates) and insulin dose was performed. For rescue study, the Kruskal-Wallis test was ﬁrst used to
determine whether differences in outcomes differed among the three
experimental groups followed by Dunn's test to correct for multiple
comparisons when the null hypothesis was false (p b 0.05). Results
are reported as mean ± standard deviation (SD).
3. Results

2.3. Micro-computed tomography (μCT) analysis
Each femur was inserted in a 6 mm tube ﬁlled with PBS. Then, the
mid-shaft and distal femur metaphysis were each scanned at an isotropic voxel size of 6 μm using a high-resolution μCT scanner (μCT50,
Scanco Medical, Brϋttisellen, Switzerland). The scan settings were as
follows: peak voltage of 70 kVp, current of 0.114 mA, integration time
of 300 ms, and 1000 projections per full rotation onto a 1024
× 1024 pixel detector. A 0.1 mm thick aluminum ﬁlter was included,
and the manufacturer's beam correction was applied. A phantom of hydroxyapatite (HA) was scanned weekly to verify the linear conversion
of attenuation to mineral density (mgHA/cm3). Following reconstruction, 1.29 mm of the mid-shaft at the point of loading (described in
the subsequent section) was evaluated using the algorithms provided
by the manufacturer to determine cortical parameters. This involved applying a Gaussian noise ﬁlter (standard deviation of 0.2 and support of
1) and a global threshold of 864.3 mgHA/cm3 (prevention study) or
973.0 mgHA/cm3 (rescue study) to segment bone from water and air.
Likewise, following reconstruction and auto-contouring (Nyman et al.,

3.1. Prevention study: effects of early continuous subcutaneous insulin infusion treatment as a function of dose
As expected for 4–5 weeks of T1D, untreated STZ-mice signiﬁcantly
weighed less and had higher non-fasting glucose levels (N500 mg/dl)
compared to non-diabetic mice (Table 1). Continuous subcutaneous insulin infusion therapy (CSII) dose dependently increased body weight of
the diabetic mice while decreasing their glucose levels as evident by the
signiﬁcant slope (not equal to 0) from linear regressions between the
measurements and insulin dose (Table 1). In addition, the P1NP marker
of bone formation and RatLAPS (C-terminal telopeptides of type I collagen) marker of bone resorption were signiﬁcantly lower and higher, respectively, for the diabetic than for non-diabetic mice (Table 1).
Interestingly, the serum marker of bone formation increased while the
serum marker of bone resorption decreased in a dose dependent manner in response to CSII (Table 1). These data suggest that absolute insulin dose might directly relate to improvements in bone formation as
well as preventing bone resorption in T1D mice. These possibilities

Table 1
Differences in selected mouse characteristics (mean ± SD) at sacriﬁce between non-diabetic and diabetic mice as well as the dose-response relationship between continuous insulin dose
and each characteristic.
Characteristic

Body weight (g)
Glucose (mg/dl)
RatLAPS (ng/ml)
P1NP (ng/ml)
a

No treatment

STZ-T1D insulin dose (IU/day)

Linear regression

Non-T1D

STZ-T1D

p-Value

0

0.0625

0.125

0.25

Slopea (p-value)

R2 (%)

27.8 ± 4.1
139 ± 19
14.5 ± 5.3
48.9 ± 4.6

20.9 ± 1.2
535 ± 63
35.4 ± 11.1
18.6 ± 4.5

b0.001
b0.001
0.001
b0.001

22.7 ± 1.7
595 ± 10
39.9 ± 18.6
26.6 ± 11.5

25.0 ± 1.0
562 ± 28
46.6 ± 2.0
29.5 ± 5.5

24.9 ± 1.8
449 ± 32
39.5 ± 13.6
39.1 ± 6.9

26.8 ± 0.9
209 ± 119
25.4 ± 7.0
63.3 ± 23.7

14.8 (b0.001)
−1626 (b0.001)
−71.0 (0.033)
155 (0.001)

54.6
84.3
25.4
54.7

Slope is the change in characteristic per change in dose as determined by linear regression of each characteristic value vs. dose (i.e., not the mean value vs. dose).
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Fig. 2. Dose-dependent relationships with cortical parameters of the femur mid-shaft. The bone structure and strength increased with an increase in insulin dose. The p-value above the
bracket is for T1D vs. Non-T1D, while the p-value below the coefﬁcient of determination (R2) is for the slope (not equal to zero when p b 0.05).

were explored further at the level of bone microarchitecture and biomechanical properties as follows.
There was also a linear relationship between CSII and structural
strength such that the cross-sectional area of the cortex (Ct.Ar), moment of inertia (Imin), and peak force increased as the dose increased
(Fig. 2). Like structural strength, short-term T1D reduced the stiffness
of the femur diaphysis when compared to non-diabetic controls, and
CSII also appeared to maintain this bone stiffness (Fig. 2) as well as
the periosteal perimeter (Ps.Pm) for diabetic mice (Table 2). While
loss of insulin following STZ injections affects bone structure at the
mid-shaft, it does not necessarily reduce the length of the femur in the
short-term. There is however a weak, positive correlation between
CSII dose and femur length (Table 2). The estimated material properties
and tissue mineral density of cortical bone (Ct.TMD) did not vary among
insulin doses, and diabetes for 4–5 weeks only decreased bending
strength, not toughness (Table 2).
A dose-dependent relationship also existed between CSII and trabecular bone volume fraction (BV/TV) as well as trabecular tissue mineral
density (Tb.TMD) (Fig. 3). As insulin dose increased, trabecular number
(Tb.N) and trabecular thickness (Tb.Th) increased (Fig. 3). Whereas

insulin at 0.25 IU/day (T1D-i0.25) appeared to prevent the diabetes-related decrease in Ct.Th (T1D-i0.25 vs. Non-T1D: p = 0.058), in Ct.Ar
(T1D-i0.25 vs. Non-T1D: p N 0.999), and in Imin (T1D-i0.25 vs. NonT1D: p = 0.514), it did not completely maintain BV/TV (T1D-i0.25 vs.
Non-T1D: p = 0.0004) and Tb.N (T1D-i0.25 vs. Non-T1D: p = 0.001).
Lastly, there was a direct linear correlation between insulin dose and
Tb.TMD (Fig. 3), but not between dose and Ct.TMD (Table 2).
3.2. Rescue study: effect of delayed continuous subcutaneous insulin infusion treatment at 0.25 IU/day
The metabolic effects that were observed after 4 weeks of conﬁrmed
T1D also existed after 8 weeks of conﬁrmed T1D such that vehicle-treated diabetic (T1D-Veh) animals had lower body weight, higher nonfasting blood glucose, higher RatLAPS, and lower P1NP compared to
non-diabetic controls (ND-Veh in Table 3). Delayed CSII at 0.25 IU/day
(T1D-i0.25) for 4 weeks did not signiﬁcantly increase body weight nor
decrease blood glucose to levels observed for ND-Veh mice (Table 3),
but delayed CSII did signiﬁcantly reduce glycated hemoglobin (HbA1c,
a marker of diabetic severity) and signiﬁcantly improved the bone

Table 2
Differences in selected properties (mean ± SD) of the femur between non-diabetic and diabetic mice as well as the dose-response relationship between continuous insulin dose and each
characteristic.
Property

b

Length (mm)
Ps.Pm (mm)
Es.Pm (mm)
Ct.Th (μm)
Ct.TMD (mgHA/cm3)
Modulus (GPa)
Bending strength (MPa)
Toughness (MJ/m3)
a
b

No treatment

STZ-T1D insulin dose (IU/day)

Linear regression

Non-T1D

STZ-T1D

p-Value

0

0.0625

0.125

0.25

Slopea (p-value)

R2 (%)

14.0 ± 0.4
4.17 ± 0.25
2.59 ± 0.19
199 ± 7
1365 ± 8
16.6 ± 3.0
285 ± 19
2.12 ± 0.48

13.7 ± 0.3
4.00 ± 0.09
2.67 ± 0.09
176 ± 9
1373 ± 10
18.5 ± 2.8
262 ± 15
2.45 ± 0.91

0.146
0.036
0.203
b0.001
0.087
0.180
0.022
0.310

13.7 ± 0.2
4.08 ± 0.10
2.71 ± 0.06
179 ± 2
1389 ± 5
16.1 ± 1.9
274 ± 17
1.96 ± 0.82

13.9 ± 0.2
4.16 ± 0.07
2.73 ± 0.08
182 ± 3
1368 ± 18
17.2 ± 2.2
272 ± 17
1.81 ± 0.29

13.9 ± 0.2
4.12 ± 0.08
2.56 ± 0.09
186 ± 7
1379 ± 7
17.9 ± 0.7
284 ± 19
2.00 ± 0.31

14.0 ± 0.1
4.31 ± 0.11
2.68 ± 0.09
193 ± 6
1377 ± 10
17.3 ± 0.7
278 ± 14
2.51 ± 0.67

0.95 (0.016)
0.86 (0.001)
=0 (0.469)
55 (b0.001)
=0 (0.500)
=0 (0.260)
=0 (0.505)
=0 (0.122)

21.9
43.7
2.6
54.5
2.5
6.8
2.3
17.5

Slope is the change in property per change in dose as determined by linear regression of each property value vs. dose.
Distance between the intercondyler groove and femoral neck as determined by calipers.
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Fig. 3. Dose-dependent relationships with trabecular parameters of the distal femur metaphysis. Trabecular bone volume fraction increased and architecture improved with an increase in
insulin dose. The p-value above the bracket is for T1D vs. Non-T1D, while the p-value below the coefﬁcient of determination (R2) is for the slope (not equal to zero when p b 0.05).

resorption and formation markers in comparison to T1D-Veh mice
(Table 3).
The CSII-related return of resorption and near return of formation
markers to non-diabetic levels (Table 3) did not necessarily translate
to a full rescue of structural stiffness and strength of the femur midshaft. While these properties were lower for the T1D-Veh mice than
for ND-Veh mice, stiffness and peak force were not signiﬁcantly different between T1D-i0.25 and ND-Veh mice indicating a partial rescue
with insulin therapy (Fig. 4). Delayed CSII had a positive effect on cortical cross-sectional area but not on Imin and Ps.Pm (Fig. 4). As observed
for 4 weeks of conﬁrmed T1D (prevention study), 8 weeks of conﬁrmed
diabetes (rescue study) did not affect Ct.TMD and the estimated material properties of cortical bone (Table 4). There were differences in femur
length and Ct.Th between Non-Veh and T1D-Veh mice, and delayed CSII
partially rescued these deﬁcits (Table 4).
With respect to trabecular micro-architecture of the distal femur
metaphysis, delayed CSII nearly restored Tb.Th and Ct.TMD to levels observed for ND-Veh mice (Fig. 5). Unlike the prevention study, there
were no signiﬁcant difference in Tb.N between 22-week old, non-diabetic and 22-week old diabetic mice in which saline was delivered via
the minipumps between weeks 4 and 8 of conﬁrmed T1D. Delayed
CSII possibly had a negative effect on Tb.N, though there was no difference between T1D-Veh and T1D-i0.25 groups (Fig. 5). Overall, delayed
CSII partially rescued BV/TV with no signiﬁcant difference between
ND-Veh and T1D-i0.25 but also no signiﬁcant difference between T1DVeh and T1D-i0.25 (Fig. 5).
4. Discussion
A pre-clinical rodent model of T1D for investigating diabetic bone
disease should consider the impact that exogenous insulin therapy
(continuous infusion or daily injections) has on the skeleton. Insulin is
universally used to treat T1D patients; thus, any pre-clinical ﬁndings related to variations in insulin administration and glycemic control are
relevant to understanding skeletal health in the T1D population. Notably, T1D treatment is distinct in this way from human type 2 diabetes
treatment, wherein multiple alternative strategies to control blood

glucose levels may be employed outside of insulin (which is often
added only as an escalation to treat hyperglycemia). To better understand the relationship between insulin and bone strength in a mouse
model of T1D, we investigated the effect of increasing doses of insulin,
delivered by CSII, on cortical and trabecular bone following STZ-induced
diabetes; and we found that insulin therapy not only dose-dependently
controls blood glucose in DBA/2 J mice but also dose-dependently preserves cortical structure and trabecular architecture of the femur diaphysis and metaphysis, respectively. Thus, with the use of implantable
osmotic minipumps, varying degrees of glycemic control and varying
deﬁcits in bone structure and architecture can be achieved by titrating
the insulin dose in STZ-induced T1D mice, especially when CSII is initiated early in the course of T1D.
Although this study cannot decouple the effect of insulin from the effect of glucose on bone, 7 out of the 10 T1D mice receiving insulin at
≥ 0.125 IU/day continued to have consistent blood glucose readings
N200 mg/dl (the weekly average over the 4-week period in the prevention study was 357 ± 89 mg/dl) while structural strength (mean ± SD)
of the femur mid-shaft was similar between these 7 mice (15.2 ± 1.8 N)
and the 10 non-T1D mice (16.5 ± 2.3 N), which typically had blood glucose readings between ~140 mg/dl and ~150 mg/dl. This ﬁnding from
Table 3
Differences in selected characteristics (mean ± SD) among vehicle-treated non-diabetic
mice, vehicle-treated diabetic mice, and insulin-treated diabetic mice.
Experimental groups
Characteristic
Body weight (g)
Glucose (mg/dl)a
Glucose (mg/dl)b
HbA1c (%)
RatLAPS (ng/ml)
P1NP (ng/ml)

1

Non-Veh
31.5 ± 2.6
150 ± 12
143 ± 13
4.3 ± 1.0
10.7 ± 1.7
39.2 ± 9.4

Adjusted p-values
2

T1D-Veh
25.4 ± 1.8
582 ± 59
581 ± 35
10.2 ± 1.0
16.8 ± 5.1
17.6 ± 3.3

3

T1D-i0.25
27.5 ± 1.7
489 ± 99
473 ± 59
7.5 ± 1.2
10.6 ± 2.3
29.3 ± 7.8

1 vs. 2
b0.001
b0.001
b0.001
b0.001
0.006
b0.001

1 vs. 3
0.007
0.003
0.017
0.037
N0.999
0.317

2 vs. 3
0.339
0.407
0.067
0.034
0.002
0.008

a
Blood glucose levels at euthanasia. Ten of the 11 mice in the T1D-Veh group and 3 of
10 mice in the T1D-i0.25 group had glucose levels N600 mg/dl, the maximum value that
the glucometer can measure.
b
Average of blood glucose measurements when the minipumps were implanted
(weeks 5–8).
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Fig. 4. Group differences in cortical bone properties (femur mid-shaft). Delayed insulin therapy via osmotic minipumps (CSII) rescued the T1D-induced loss in cortical cross-sectional area
but not the loss in the moment of inertia. Even though the bone structure was not fully restored, delayed CSII partially improved whole-bone stiffness and strength. a: adjusted p-value b
0.05 vs. ND-Veh and b: adjusted p-value b 0.05 vs. T1D-Veh.

the pre-clinical mouse model suggests that glycemic control alone may
not fully account for the structural strength improvements observed
with CSII, thereby suggesting treatment at an optimal insulin dose and
mode of delivery may positively impact skeletal growth through additional mechanisms not dependent on blood glucose alone.
While insulin therapy is known to preserve bone strength and
trabecular architecture in STZ rodents (Hie et al., 2011; Rao
Sirasanagandla et al., 2014), whether insulin can restore bone structure
and strength is unknown for diabetic rodents. Four weeks of CSII partially
rescued cortical structure and structural strength when started 6 weeks
after the ﬁrst STZ injection (i.e., 4 weeks of established, uncontrolled diabetes). Thus, for those newly diagnosed with T1D or for those who are
non-complaint or under-treated with insulin (poor control), optimizing
insulin therapy using means such as CSII may prove beneﬁcial in promoting peak bone mass and strength. Additional studies will be necessary to
determine if optimizing further insulin therapy (using higher insulin
doses and/or longer duration of insulin treatment) may have an even
more profound effect on rescuing the skeletal integrity in T1D.
In the STZ model, diabetes deleteriously affects both trabecular and
cortical bone, and CSII does not necessarily preserve both cortical structure and trabecular architecture to the same extent. CSII dose-dependently increased both Tb.Th (Fig. 3) and Ct.Th (Table 1). While this
increase prevented a decrease in Ct.Ar and Imin of the femur diaphysis
(Fig. 2), it did not translate to complete preservation of trabecular BV/
TV of the distal femur metaphysis likely because the Tb.N remained
low in the CSII-treated T1D mice (Fig. 3). This differential effect of CSII
on trabecular and cortical bone could be due to differences in the expression or sensitivity of insulin receptors on bone cells between the

two compartments. Also, in growing mice, the cortex undergoes modeling in which the cross-sectional area and moment of inertia of the cortex increases (Ferguson et al., 2003). Trabecular bone of the
metaphysis on the other hand undergoes remodeling, thereby altering
trabecular architecture of the metaphysis. Thus, the high dose of insulin
and duration of CSII used in the prevention study herein were sufﬁcient
to maintain normal cortical modeling of the mid-shaft (periosteal perimeter was positively associated with insulin dose, Table 2), but were
not sufﬁcient to maintain normal trabecular remodeling. Of interest,
the marker of resorption (RatLAPS) and the marker of formation
(P1NP) were 1.75 times and 1.29 times higher, respectively, for T1Di0.25 than for non-treated, non-T1D mice indicating resorption activity
may still have outpaced formation activity in the insulin-treated T1D
mice at the highest dose.
In the rescue study, CSII treatment of diabetic mice increased Tb.Th
without affecting Tb.N (Fig. 5). Even though the resorption and formation markers returned to near non-diabetic levels at 0.25 IU/day (0.99
and 0.75 times ND-Veh levels, respectively), 4 weeks was not sufﬁcient
for new trabeculae to form between existing trabeculae. Curiously,
there was no difference in Tb.N between non-diabetic and diabetic
mice (vehicle treated) in the rescue study unlike the prevention study.
The diabetes may have accelerated the loss in Tb.N, but by 22 weeks
of age, the typical age-related decrease in Tb.N for the non-T1D mice
possibly caught up with diabetic animals. With respect to cortical
bone, diabetes did not affect endosteal perimeter in the prevention
and rescue studies, but it did lower periosteal perimeter (Tables 2
and 4) suggesting delayed CSII started to increase periosteal bone
formation in the diabetic mice.

Table 4
Differences in select properties (mean ± SD) of the femur among vehicle-treated non-diabetic mice, vehicle-treated diabetic mice, and insulin-treated diabetic mice.
Property

Length (mm)
Ps.Pr (mm)
Es.Pr (mm)
Ct.Th (μm)
Ct.TMD (mgHA/cm3)
Modulus (GPa)
Bending strength (MPa)
Toughness (MJ/m3)
a

Experimental groups

Adjusted p-values

Non-Veh1

T1D-Veh2

T1D-i0.253

1 vs. 2

1 vs. 3

2 vs. 3

14.4 ± 0.3
4.56 ± 0.21
2.79 ± 0.25
182 ± 14
1345 ± 22
16.0 ± 1.6
269 ± 26
1.80 ± 0.60

13.8 ± 0.6
4.34 ± 0.27
2.87 ± 0.35
163 ± 14
1332 ± 20
16.6 ± 2.1
267 ± 28
1.74 ± 0.61

14.2 ± 0.3
4.36 ± 0.19
2.65 ± 0.18
176 ± 13
1340 ± 22
17.0 ± 1.3
281 ± 26
1.51 ± 0.53

0.009
0.028

0.273
0.318
0.192a
0.532

0.671
N0.999

Single p-value comes from the Kruskal-Wallis test indicating no difference among the groups.

0.009
0.274

0.321
0.487
0.930

0.363
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Fig. 5. Group differences in trabecular bone properties (distal femur metaphysis). Delayed insulin therapy via osmotic minipumps (CSII) signiﬁcantly improved trabecular thickness nearly
restoring Tb.Th to the level of non-T1D controls. It also had positive effect on trabecular tissue mineral density, but little effect on the trabecular bone volume fraction. a: adjusted p-value b
0.05 vs. ND-Veh and b: adjusted p-value b 0.05 vs. T1D-Veh.

The ﬁndings that insulin incrementally improves skeletal parameters both in the cortical and trabecular compartments is consistent
with previous studies showing that the elimination of the insulin receptor in osteoprogenitors in male mice results in lower trabecular bone
volume fraction and thinner trabeculae as well as thinner cortices and
a smaller moment of inertia in the diaphysis, which manifests as decreased structural strength of the femur mid-shaft, independent of
body mass (Fulzele et al., 2010; Thrailkill et al., 2014). Thus, insulin
may directly improve bone formation through its effects on osteoblastic
activity in both the trabecular and cortical compartments.
There are several limitations to the reported ﬁndings. While markers
of resorption and formation provided insight into how CSII in the context of T1D affects bone metabolism, bone histology and dynamic
histomorphometry would further establish how insulin therapy preserved or partially rescued bone structure and architecture. The sample
size in the prevention study precluded detecting signiﬁcant differences
in the selected bone properties among the different groups of escalating
insulin dose. Obviously, there is overlap in each property among the different insulin groups, but overall bone properties improve with an increase in insulin dose for T1D mice. The slope and R2 of these dose
relationships depend on the dynamic range in the given property (i.e.,
how much the property differs between non-T1D and T1D mice), so
we cannot conclude that insulin dosing has more of an effect on Tb.Th
(R2 = 68.8%) than on Imin (R2 = 44.3%). Without longitudinal measurements (e.g., in vivo μCT), our ex vivo measurements are unable to quantify the relative change in a bone property over the treatment period as
a function of dose, and they are less sensitive to detecting the rescue effect of delayed CSII. Ultimately though, assessment of bone strength requires destructive testing, and early and delayed CSII does appear
beneﬁcial to this biomechanical property. Finally, only male mice were
used in these studies, thus limiting our conclusions to only one sex.
5. Conclusion
As the dose of insulin increased with 4 weeks of CSII therapy when
administered soon after the onset of frank diabetes, cortical structure
and strength as well as trabecular architecture improved, though trabecular number was not fully restored at the highest dose. This appeared to occur without fully lowering non-fasting blood glucose to
non-diabetic levels. Delayed CSII for 4 weeks in the T1D model rescued
certain structural properties, namely cross-sectional area of the cortex,
and partially rescued structural strength. It also rescued trabecular

thickness, but not trabecular bone volume fraction of the femur
metaphysis, despite nearly restoring markers of bone resorption and
bone formation to non-diabetic levels. Thus, these studies show that
continuous insulin therapy early after diabetes onset can promote normal bone mass accrual in a dose-dependent fashion, while delayed
treatment with insulin can partially improve strength and structure of
bone. Ultimately, these studies provide pre-clinical evidence that either
approach to optimize insulin dose, duration, and mode of administration may prove relevant to improving bone structure and quality and reduce fracture risk in humans with T1D.
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